Compare Range Nuclear Renaissance ETF (NUKZ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Range Nuclear Renaissance ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Range Nuclear Renaissance ETF trades at $57.75 (market cap $662.96M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 7.6× Range Nuclear Renaissance ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Range Nuclear Renaissance ETF for 23 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NUKZ | TVTX | |
|---|---|---|
Market Cap | $662.96M | $5.02B |
Volume | 99,094 | 2,060,842 |
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $67.52 |
52-Week Low | $58.42 | $26.79 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUKZ (Range Nuclear Renaissance Index ETF) trades at $60.37, showing minimal daily movement (+0.18%). The technical picture remains bearish with moving averages signaling strong selling pressure, though oscillators suggest neutral momentum. Recent industry developments include Google's 3.6 GW nuclear deal with Constellation Energy and record global nuclear power generation, creating positive sector tailwinds despite the ETF's current technical weakness.
The nuclear energy sector faces both significant catalysts and challenges. Strong demand from AI data centers and federal support for new projects provide growth opportunities, while supply chain bottlenecks and execution risks remain concerns. With the ETF trading near support levels, investors are watching for fundamental improvements to drive price recovery.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Range Nuclear Renaissance ETF
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
